Baltimore, MD – According to citybiz, Governor Wes Moore welcomed Samsung Biologics, South Korea’s largest biotechnology firm, as it announced plans to establish its inaugural United States manufacturing facility in Rockville, Maryland. The announcement, made on December 30, 2025, underscores Maryland’s growing prominence in the biotechnology sector and promises significant economic benefits for the state.
The new facility will focus on the production of biologic medicines, including monoclonal antibodies and other complex therapeutics essential for treating diseases such as cancer and autoimmune disorders. Samsung Biologics selected Rockville for its strategic location within the I-270 technology corridor, which is renowned for hosting a cluster of life sciences companies and research institutions. This decision aligns with the company’s global expansion strategy to meet increasing demand for biopharmaceuticals in the North American market.
Governor Moore highlighted the partnership during a press event at the State House in Annapolis, emphasizing how it reflects Maryland’s commitment to fostering innovation and job creation. “This is a game-changer for our state’s economy,” Moore stated. “By bringing Samsung Biologics to Maryland, we’re not just creating jobs; we’re positioning our state as a leader in the global fight against disease through cutting-edge biotechnology.” The governor’s administration has been actively promoting Maryland as a hub for life sciences, leveraging incentives such as tax credits and workforce development programs to attract major players like Samsung.
The Rockville site is expected to commence operations in early 2027, following construction that will begin in the spring of 2026. Initial phases will include a 50,000-square-foot manufacturing space equipped with state-of-the-art cleanroom technology for bioprocessing. Samsung Biologics anticipates hiring approximately 150 skilled workers in the first year, with projections for up to 300 positions over the next five years. These roles will encompass engineers, scientists, quality control specialists, and support staff, drawing from Maryland’s robust talent pool at nearby institutions like the University of Maryland and Johns Hopkins University.
One key statistical highlight from the announcement is the projected $200 million investment by Samsung Biologics in the facility over its first three years, which includes equipment, infrastructure, and training programs. This infusion of capital is anticipated to generate an additional $500 million in economic output for the region through direct and indirect effects, according to preliminary estimates from the Maryland Department of Commerce.
As an example of the facility’s potential impact, Samsung officials cited their expertise in contract development and manufacturing organization (CDMO) services, which have already supported over 200 global clients. In Rockville, the plant will prioritize partnerships with U.S.-based pharmaceutical companies, accelerating the development of therapies that have previously faced production bottlenecks overseas.
The move comes amid a broader surge in Maryland’s biotech industry, which employs over 40,000 people statewide and contributes more than $20 billion annually to the economy. Governor Moore’s office noted that this project builds on recent successes, such as expansions by AstraZeneca and GlaxoSmithKline in the state. To support the initiative, the administration will collaborate with Montgomery County officials to streamline permitting and provide grants for employee training through the Maryland Workforce Exchange.
Local leaders, including Rockville Mayor Bridget Donnellan, praised the announcement as a boon for the community. “Rockville’s biotech ecosystem will thrive with Samsung’s presence, bringing innovation and prosperity to our residents,” Donnellan said. The facility’s location near federal agencies like the National Institutes of Health further enhances its appeal, facilitating research collaborations that could lead to breakthroughs in public health.
Challenges ahead include ensuring a sustainable supply chain for raw materials and navigating regulatory approvals from the U.S. Food and Drug Administration. However, Samsung Biologics’ track record, with a capacity exceeding 600,000 liters globally, positions it well to overcome these hurdles.
This development reinforces Maryland’s strategy to diversify its economy beyond traditional sectors, focusing on high-growth areas like biotechnology and advanced manufacturing. As the state prepares for the facility’s opening, stakeholders anticipate it will not only boost employment but also elevate Maryland’s profile in international trade and innovation.
For more information, visit citybiz.